On June 1, 2021 Amgen (NASDAQ: AMGN) reported that it will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting at 4:00 p.m. ET on Friday, June 4, 2021 (Press release, Amgen, JUN 1, 2021, View Source [SID1234583310]). David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team, will discuss clinical data being presented on the Company’s recently FDA-approved KRASG12C inhibitor LUMAKRAS (sotorasib), anti-FGFR2b antibody bemarituzumab and delta-like ligand 3-targeting half-life extended bispecific T-cell engager (BiTE) tarlatamab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given at certain investor and medical conferences, can be accessed on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.